KFDA approves subcutaneous formulation of Orencia for rheumatoid arthritis

Published: 2013-06-14 06:57:00

Updated: 2013-06-14 06:57:00

The Ministry of Food and Drug Safety (MFDS) has approved a subcutaneous formulation of Orencia (abatacept; BMS Korea) for the reduction of signs and symptoms in adults with moderate to severe rheumatoid arthritis.

The once-weekly, self-injectable subcutaneous formulation of Orencia is a fixed 125mg dose injection.

Orencia is already available in an intravenous formulation that is indicat...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.